Predict your next investment

Infinovo company logo
CONSUMER PRODUCTS & SERVICES | Health & Wellness (non-internet/mobile) / Weight & Health Management
infinovo.com

See what CB Insights has to offer

Founded Year

2016

Stage

Series C | Alive

About Infinovo

Infinovo is a China-based medical technology company that focuses on glucose monitoring for diabetes.

Infinovo Headquarter Location

3rd Floor, 6th building No.888 Zhujiang Road

Nantong, Jiangsu, 226400,

China

+86-512-67418769

Latest Infinovo News

Vertex Ventures Leads Series B Round In Chinese Glucose Monitoring Device Developer Infinovo

Jul 28, 2020

July 29, 2020 — 04:11 Vertex Ventures has led a series B round financing in Infinovo, a Chinese innovative medical device manufacturer. The proceeds of this financing worth tens of millions of RMB will be mainly used for the registration and approval of the company’s new product – continuous glucose monitoring (CGM) system and the channel layout at home and abroad. Founded in 2016, Infinovo is an innovative medical technology company, focusing on developing an accurate and affordable CGM for patients which will be available for both Type 1 and Type 2 Diabetics. The Glunovo i3 CGM is the first-generation CGM product from Infinovo. It is a small wearable device that enables monitoring of patient’s Blood Glucose levels continuously, capturing trends in BG levels and alerts the patient to highs and lows. The sensor lasts 14 days and the transmitter will not require replacing for at least 4 years. According to IDF statistics, there were 116 million diabetic patients in China in 2019, and the number of patients continued to be the first in the world. Among them, more than 10 million people need to use continuous glucose monitoring products. The huge patient base will support a broad market space. It is expected that China CGM market is expected to reach RMB 4 billion; in addition, some institutions predict that the total sales volume of the global CGM market will exceed US$4 billion in 2020 and continue to maintain a trend of rapid growth. “There are currently 425 million adults suffering from diabetes in the world, and there are about 110 million patients in China alone. The needs from huge patient population make CGM one of the fastest growing fields in the global medical industry,” said Liu Tianran, investment executive director at Vertex Ventures. “Infinovo has been deeply involved in diabetes management and has advantages in industrial layout, product technology and market channels. After just a few years of development, its several products have been recognized by clinical and regulatory authorities at home and abroad.” Prior to this, Infinovo secured a series A round financing from Loyal Valley Capital, Prosperico Ventures, and Rays Venture Capital.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Infinovo

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Infinovo is included in 3 Expert Collections, including Digital Health.

D

Digital Health

11,760 items

D

Diabetes

1,750 items

M

Medical Devices

7,884 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Infinovo Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Infinovo Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.